



BioAegis Therapeutics and TH Chan Harvard School of Public Health Awarded 3-Year \$2.8MM NIH Grant to Study Plasma Gelsolin Immunotherapy to Limit Antibiotic-Resistant Pneumonia

Grant Will Fund Plasma Gelsolin as a Host-Targeted Therapeutic to Address Antibiotic Resistance

BOSTON, MA and MORRISTOWN, NJ, (**BIOAEGIS THERAPEUTICS**) June 09, 2016 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin's (pGSN) role in immune function announced that the National Institute of Allergy and Infectious Diseases awarded a 3-year \$ 2.8 million grant to a partnership between the company and Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications entitled: "Partnerships for the Development of Host-Targeted Therapeutics to Limit Antimicrobial Resistance."

Plasma Gelsolin

Plasma gelsolin (pGSN) becomes depleted in a wide range of inflammatory conditions, and critically low levels associate with significant morbidity and mortality in animals and humans. pGSN replacement attenuates or eliminates these complications in 18 independent animal injury models. Based on recent breakthrough findings by Dr. Lester Kobzik at the TH Chan Harvard School of Public Health, plasma gelsolin replacement therapy markedly decreased mortality of murine pneumonia due to its stimulation of macrophages' ability to ingest and kill Gram-positive and Gram-negative bacteria.

BioAegis Therapeutics is entering into Phase 2a/2b clinical trials to treat Severe Community-Acquired Pneumonia (SCAP), a leading cause of death in the US and around the world despite antibiotics and improved levels of care.

Susan Levinson, Ph.D., Chief Executive Officer of BioAegis stated, "We are very pleased to have been awarded this grant. The potential to directly augment the immune response to varied pathogens in the face of sub-optimal or ineffective antibiotics is a new and exciting approach and is consistent with plasma gelsolin's role in innate immunity."

Thomas Stossel, the discoverer of gelsolin and BioAegis' Chief Scientific Advisor, commented, "These resources present a great opportunity to add the increasingly troubling public health challenge of antibiotic resistance to pGSN's already extensive therapeutic potential."

About BioAegis Therapeutics

Founded by a group of highly experienced pharmaceutical and business executives, BioAegis' mission is to harness the body's innate immune system to address adverse outcomes in diseases driven by inflammation and infection.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373

Email: scordovano@bioaegistherapeutics.com

www.bioaegistherapeutics.com